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Abstract
A rotavirus VP4 gene P[6] allele has been documented in a number of countries to be characteristically associated with an endemic
predominantly asymptomatic infection in neonates in maternity hospital nurseries. The mechanisms underlying the endemicity and
asymptomatic nature of such neonatal infections remain unknown. Rotavirus strains sharing this same P genotype, however, have more
recently been recovered from an increasing number of symptomatic diarrheal episodes in infants and young children in various parts of the
world. Previously, we have shown that an asymptomatic P[6] rotavirus neonatal infection is not associated with a unique VP7 (G) serotype
but may occur in conjunction with various G types. Although amino acid sequence comparisons of the VP4 gene between selected
“asymptomatic” and “symptomatic” P[6] rotavirus strains have been reported and yielded information concerning their VP4 genotypes,
serotypic comparisons of the outer capsid spike protein VP4 of such viruses have not been studied systematically by two-way cross-
neutralizations. We determined the VP4 neutralization specificities of four asymptomatic and four symptomatic P[6] strains: two each of
asymptomatic and symptomatic strains by two-way tests, and two each of additional asymptomatic and symptomatic strains by one-way
tests. Both asymptomatic and symptomatic P[6] strains were shown to bear similar, if not identical, VP4 neutralization specificities. Thus,
P[6] rotavirus strains causing asymptomatic or symptomatic infections did not appear to belong to unique P (VP4) serotypes. In addition,
a close VP4 serotypic relationship between human P[6] rotavirus strains and the porcine P[6] rotavirus Gottfried strain was confirmed.
© 2003 Elsevier Inc. All rights reserved.
Introduction
Group A rotaviruses remain the single most important
etiologic agents of severe diarrhea in infants and young
children worldwide. Rotavirus disease is estimated to be
responsible for approximately up to 520,000 deaths each
year among children  5 years of age predominantly in
developing countries (Miller and McCann, 2000). In the
United States, it is estimated that approximately 2.7 million
infants and young children develop rotavirus diarrhea an-
nually, resulting in approximately 20 deaths, about 50,000
hospitalizations, and more than 500,000 medical visits at an
annual societal cost of more than $1 billion (Bresee et al.,
1999; Glass et al., 1994; Kapikian et al., 2001). Thus, the
availability of a safe and effective rotavirus vaccine capable
of preventing this enormous health burden would represent
a global public health breakthrough.
In 1975, only 2 years after first being identified in hu-
mans, rotaviruses were detected in a number of countries in
the stools of predominantly asymptomatic neonates in new-
born nurseries (Albrey and Murphy, 1976; Bishop et al.,
1976; Chrystie et al., 1975; Madeley et al., 1978; Murphy et
al., 1975; Totterdell et al, 1976). These early reports as well
as reports published later (Bryden et al., 1982; Cicirello et
al., 1994; Das et al., 1994; Garbag-Chenon et al., 1985;
Grillner et al., 1985; Haffejee et al., 1990; Jayashree et al.,
1988; Kilgore et al., 1996; Linhares et al., 2002; Perez-
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Schael et al., 1984; Spencer et al., 1988; Steele and Alex-
ander, 1987; Steele et al., 2002; Sukumaran et al., 1992;
Tam et al., 1990; Tietzova et al., 1995; Tufvesson et al.,
1986) showed that (i) a majority of the infected newborn
babies were characteristically symptom free or only mini-
mally symptomatic and (ii) a single rotavirus strain with a
distinct electropherotype persisted in a neonatal nursery for
a long period of time. The latter observation was in sharp
contrast to rotavirus strains circulating in the surrounding
community, that demonstrated a high degree of genomic
variability. Previously, selected “endemic nursery” rotavi-
rus strains recovered from asymptomatic neonates in four
different countries (Australia, Sweden, the United King-
dom, and Venezuela) were analyzed by (i) neutralization,
(ii) RNA–RNA hybridization, or (iii) VP4 gene sequence
analysis. It was reported that (i) there was no correlation
between a specific G serotype of rotavirus and the occur-
rence of asymptomatic or mild infections among newborn
babies (Hoshino et al., 1985) and (ii) the VP4 genes, which
were the only conserved genes among the four neonatal
rotavirus strains tested as determined by RNA–RNA hy-
bridization (Flores et al., 1986), were unique to each of
these nursery strains and were closely related to each other
(95.5 to 97.5% nucleotide identity) (Gorziglia et al., 1988,
1990). Because of (i) the possible association between this
distinct VP4 gene allele (P2A[6]) and the observed attenu-
ation phenotype in neonates and (ii) an observation report-
ing that an asymptomatic or mild infection of neonates with
one of such endemic nursery rotavirus strains conferred
protection against clinically severe disease due to reinfec-
tion during the first 3 years of life (Bishop et al., 1983), two
such P[6] rotavirus strains were developed independently as
candidate vaccines. One (M37) was of Venezuelan origin
and the other (RV3) of Australian origin, and each under-
went phase I to early phase II clinical trials (Barnes et al.,
1997, 2002; Flores et al., 1990; Midthun et al., 1991; Perez-
Schael et al., 1994; Vesikari et al., 1991). Moreover, RV3 is
still under study as a vaccine candidate (Barnes et al., 2002).
Of note was the finding that the VP4 of the porcine rotavirus
Gottfried strain which was originally isolated from a diar-
rheic pig in the U.S.A. (Bohl et al., 1984) was closely
related genetically (the Gottfried VP4 shares 87.7–89.3%
amino acid identity with asymptomatic P[6] VP4s) and
antigenically to human nursery strains with P2A[6] speci-
ficity and therefore was classified as a subtype (P2B[6]) (Li
and Gorziglia, 1993).
Recent epidemiologic surveys of rotavirus strains have
reported that strains bearing the VP4 gene P[6] allele in
conjunction with various G types are recovered from an
increasing number of infants and young children with diar-
rhea throughout the world (for reviews, see Cunliffe et al.,
2001; Gentsch et al., 1996; Hoshino and Kapikian, 2000).
Such observations have aroused renewed scientific interest
as to whether any differences exist in the genetic make-up
between “asymptomatic” and “symptomatic” P[6] rotavirus
strains. Efforts have been made, therefore, to seek a corre-
lation between amino acid sequence differences of selected
genes [which included VP4 (or VP8*), VP7, NSP1, or
NSP4 gene, each of which had been reported in an animal
model to be virulence-associated (Bridger et al., 1998;
Broome et al., 1993; Hoshino et al., 1995; Offit et al.,
1986)], of asymptomatic or symptomatic P[6] rotavirus
strains and the observed differences in virulence phenotype
(Kirkwood et al., 1996; Lee et al., 2000, 2001; Pager et al.,
2000; Palombo and Bishop, 1994; Santos et al., 1994).
However, appreciable amino acid differences in such se-
lected genes have not been identified consistently thus far.
Although one-way neutralization tests have been reported
for four asymptomatic strains (M37, 1076, McN, and ST3)
(Gorziglia et al., 1990) and two symptomatic strains
(MW23 and US1205) (Cunliffe et al., 2000; Kirkwood et
al., 1999) and were consistent with the observed genotypes,
it is still not known if they are identical by reciprocal
neutralizations tests. The objectives of this study were three-
fold, as follows: (i) to determine the reciprocal two-way
neutralization specificity of the outer capsid spike protein
VP4 of two asymptomatic (M37 and ST3) and two symp-
tomatic (MW23 and US1205) P[6] strains; (ii) to determine
the one-way neutralization specificity of two additional
asymptomatic (1076 and McN) and two additional symp-
tomatic (INL1 and R143) strains; and (iii) to determine the
extent of the subtype relationship of the porcine rotavirus
Gottfried strain VP4 by neutralization with these asymp-
tomatic and symptomatic strains.
Results
Generation of single VP7 or VP4 gene substitution human
 human, human  bovine, or porcine  human
rotavirus reassortants as well as hyperimmune
guinea pig antiserum to each reassortant
We generated (i) two single VP7 gene substitution hu-
man  human rotavirus reassortants, each of which had 10
genes from human P2A[6] rotavirus M37 or ST3 strain and
only the VP7 gene from human rotavirus DS-1 strain (G2);
(ii) three single VP4 gene substitution human  bovine
rotavirus reassortants, each of which had only the VP4 gene
of human P2A[6] rotavirus M37, MW23, or US1205 strain
and the remaining 10 genes of bovine rotavirus UK strain
(G6); and (iii) one single VP7 gene substitution porcine 
human rotavirus reassortant which had 10 genes from por-
cine rotavirus Gottfried strain (P2B[6],G4) and only the
VP7 gene from DS-1 strain (Fig. 1). Reassortants M37 
DS-1 (P2A[6],G2) and M37  UK (P2A[6],G6) were con-
structed to analyze whether a different VP7 gene back-
ground (DS-1 or UK) affects qualitatively or quantitatively
the immunologic and biologic properties of the M37 VP4
protein of the reassortant because of a “fit” difference (Chen
et al., 1992). We have chosen strains DS-1 and UK to
generate various reassortants because (i) VP7 of the DS-1 or
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UK is the least cross-reactive by neutralization and thus the
VP4 and VP7 responses are readily dissociated and (ii)
various single VP7 (DS-1 or UK) substitution reassortants
had been used extensively by us in characterizing VP4
neutralization specificities of various rotavirus strains
(Hoshino and Kapikian, 1996). Hyperimmune antiserum to
each of the six reassortants was generated by immunizing
guinea pigs which were free of rotavirus antibodies by
neutralization (antibody titer  1:20 versus M37). At least
two guinea pigs were used for immunization against each
reassortant in an attempt to obtain an accurate neutralization
profile.
Analysis of neutralization profile of guinea pig
hyperimmune antiserum raised against VP4 protein of
human or porcine P[6] rotavirus strains
Table 1 summarizes the antigenic characterization of
human or porcine P2A[6], P2B[6], or P?[6] rotavirus VP4s.
Previously, hyperimmune guinea pig antiserum raised
against asymptomatic 1076 VP4 expressed by a baculovirus
recombinant was reported to neutralize selected asymptom-
atic endemic nursery strains M37, McN, and ST3 (Gorziglia
et al., 1990). We confirmed and extended this observation
by showing the existence of a two-way VP4 antigenic re-
lationship among the 1076, M37, and ST3 strains (Table 1).
Similarly, by one-way cross-neutralization, symptomatic
strains MW23 and US1205 were previously shown to be
neutralized significantly by hyperimmune guinea pig anti-
serum to ST3 (asymptomatic P2A[6] strain)  DS-1 (Cun-
liffe et al., 2000; Kirkwood et al., 1999). This finding was
confirmed and extended further in this study by two-way
cross-neutralization: antibodies to the MW23 VP4 or
US1205 VP4 neutralized significantly all four asymptom-
atic strains including the ST3 virus. Similarly, the asymp-
tomatic M37 VP4 was shown to be related antigenically in
a two-way fashion to the symptomatic MW23 or US1205
VP4. Furthermore, two additional symptomatic P?[6]
strains examined (Indian INL1 strain and Brazilian R143
strain) were neutralized significantly by antibodies to
asymptomatic (M37 and ST3) or symptomatic (MW23 and
US1205) VP4s and thus could be classified as P2A strains.
Thus, this study showed that both asymptomatic and symp-
tomatic P[6] strains bore similar, if not identical, neutral-
ization specificities. Hyperimmune guinea pig antiserum
raised against M37  DS-1 or M37  UK demonstrated a
similar neutralization profile against both asymptomatic and
symptomatic P[6] strains (Table 1), indicating that the dif-
ferent genetic background (DS-1 or UK) of each reassortant
did not affect qualitatively or quantitatively the immuno-
logic and biologic characteristic of the M37 VP4.
All eight guinea pig hyperimmune antisera raised to the
VP4 protein of asymptomatic or symptomatic human
P2A[6] or P?[6] rotavirus strains neutralized the porcine
rotavirus Gottfried strain (P2B[6]) efficiently with titers
ranging from identical to eight-fold less than to the human
homotypic P2A[6] or P?[6] rotavirus strains, indicating that
both human and porcine P[6] rotavirus VP4s carried similar
neutralization specificities. These results are in accord with
those reported previously by Gorziglia et al. (1990). How-
ever, antibodies to the Gottfried VP4 neutralized human
P2A[6] or P?[6] strains 8- to 16-fold less efficiently than the
Gottfried virus (Table 1), indicating that in this direction the
VP4 relationship, although within 20-fold of the Gottfried
virus by neutralization (i.e., 20 antibody units, wherein 1
unit equals the least amount needed to produce the response
being studied) (Hoshino and Kapikian, 1996), was not as
close as that noted above. In addition, although our results
are also consistent with a designation of Gottfried as a
subtype of P2A, i.e., as P2B, as suggested later by Li and
Gorziglia, our neutralization findings differ from the latter
report in which guinea pig serum raised to recombinant
Gottfried VP4 neutralized asymptomatic human P2A[6]
neonatal viruses within 20 antibody units, whereas guinea
pig serum to a recombinant asymptomatic human neonatal
1076 strain VP4 did not neutralize Gottfried virus within 20
antibody units (Li and Gorziglia, 1993). Thus, in that study
Gottfried strain had the characteristics of a prime strain
when compared to the asymptomatic human strains. In our
study as stated above, each of the eight guinea pig sera
raised to the established or newly established human P2A[6]
strains (four to asymptomatic and four to symptomatic
strain reassortants) neutralized Gottfried virus more effi-
Fig. 1. Electrophoretic migration patterns of genomic RNAs of human
rotavirus DS-1 strain (lane 1), reassortant M37  DS-1 (lane 2), human
rotavirus M37 strain (lane 3), reassortant M37  UK (lane 4), bovine
rotavirus UK strain (lane 5), reassortant MW23  UK (lane 6), human
rotavirus MW23 strain (lane 7), human rotavirus ST3 strain (lane 8),
reassortant ST3  DS-1 (lane 9), human rotavirus DS-1 strain (lane 10),
reassortant Gottfried  DS-1 (lane 11), porcine rotavirus Gottfried strain
(lane 12), human rotavirus US1205 strain (lane 13), reassortant US1205 
UK (lane 14), and bovine rotavirus UK strain (lane 15) in 10% polyacryl-
amide gel. Genomic RNAs were electrophoresed at 13 mA for 15 h and the
resulting migration patterns were visualized by staining of gel with silver
nitrate.
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Table 1
Antigenic characterization of human or porcine P[6] rotavirus VP4s by analysis of their guinea pig hyperimmune antiserum neutralization profile
Rotavirus A*/S* Reciprocal of 60% PRN antibody titer of guinea pig hyperimmune antiserum to indicated rotavirus reassortant******
Strain Country
of origin
Year
collected
Host P type
[genotype]
G type M37  DS-1
(P2A[6],G2)
53084**
M37  UK
(P2A[6],G6)
58742
ST3  DS-1
(P2A[6],G2)
45063
ST3  DS-1
(P2A[6],G2)
45064
MW23  UK
(P2A[6],G6)
58640
MW23  UK
(P2A[6],G6)
58641
US1205  UK
(P2A[6],G6)
57674
US1205  UK
(P2A[6],G6)
57675
Gott  DS-1
(P2B[6],G2)
44728
Gott  DS-1
(P2B[6],G2)
44729
M37a Venezuela 1982 Human 2A [6] 1 A 2560 *** 10240 2560 (1) 2560 (1) 5120 (0.5) 640 (2) 2560 (1) 2560 (2) 80 (16) 160 (16)
1076b Sweden 1983 Human 2A [6] 2 A 40960 ***** 2560 (4) 10240 5120 1280 (2) 320 (4) 2560 (1) 2560 (2) 10240 10240
McNb Australia 1980 Human 2A [6] 3 A 2560 (1) 2560 (4) 2560 (1) 2560 (1) 2560 (1) 640 (2) 10240 (0.25) 5120 (1) 160 (8) 320 (8)
ST3c UK 1975 Human 2A [6] 4 A 1280 (2) 2560 (4) 2560 2560 5120 (0.5) 640 (2) 5120 (0.5) 1280 (4) 80 (16) 160 (16)
MW23d Malawi 1997/99 Human 2A [6] 8 S 2560 (1) 2560 (4) 2560 (1) 640 (4) 2560 1280 10240 (0.25) 10240 (0.5) 160 (8) 320 (8)
US1205e USA 1996/97 Human 2A [6] 9 S 2560 (1) 1280 (8) 640 (4) 640 (4) 2560 (1) 640 (2) 2560 5120 80 (16) 320 (8)
INL1f India 1994 Human ? [6] 9 S 1280 (2) 2560 (4) 2560 (1) 2560 (1) 2560 (1) 640 (2) 2560 (1) 5120 (1) 160 (8) 320 (8)
R143g Brazil 1999 Human ? [6] 9 S 5120 (0.5) 5120 (2) 5120 (0.5) 5120 (0.5) 5120 (0.5) 1280 (1) 5120 (0.5) 5120 (1) 160 (8) 320 (8)
Gottfriedh USA 1983 Porcine 2B [6] 4 S 640 (4) 1280 (8) 2560 (1) 640 (4) 1280 (2) 320 (4) 2560 (1) 2560 (2) 1280 2560
DS-1i USA 1976 Human 1B [4] 2 S 10240 **** 80 5120 5120 80 80 80 80 10240 10240
UKj UK 1975 Bovine 7 [5] 6 S 80 10240 80 80 10240 2560 10240 10240 80 80
Note. Since two guinea pig hyperimmune antisera raised against M37  DS-1 or M37  UK demonstrated a similar neutralization profile, neutralization data for only one serum/reassortant are shown.
* A  asymptomatic infection; S  symptomatic infection.
**Guinea pig identification number.
***VP4 homotypic values in bold.
****VP7 homotypic values underlined.
*****VP4 and VP7 homotypic values in bold and underlined.
******Number in parentheses after each titer indicates the fold difference in titer relative to the homologous titer.
a Perez-Schael et al. (1984).
b Hoshino et al. (1985).
c Wyatt et al. (1983).
d Cunliffe et al. (2000).
e Ramachandran et al. (1998).
f Ramachandran et al. (2000).
g Santos et al. (2001).
h Bohl et al. (1984).
i Wyatt et al. (1982).
j Woode et al. (1975).
4
Y.H
oshin,
et
al./Virology
316(2003)1
–8
ciently than defined for the neutralization of each of these
strains by guinea pig sera raised to the Gottfried virus
reassortant. We have no conclusive explanation for these
conflicting results. However, it is possible that this may
have resulted from the different source of antigens (ex-
pressed recombinant VP4 proteins versus reassortants rota-
virus VP4s) used to generate the antibodies. In addition, the
lower titer of guinea pig antiserum raised against recombi-
nant VP4 proteins may have played some role in these
conflicting results.
Discussion
Rotavirus infections in newborns continue to attract con-
siderable attention of both clinical and basic research inves-
tigators worldwide as evidenced by a large number of pub-
lications (e.g., Albrey and Murphy, 1976; Bishop et al.,
1976; Bryden et al., 1982; Chrystie et al., 1975; Cicirello et
al., 1994; Das et al., 1994; Garbag-Chenon et al., 1985;
Grillner et al., 1985; Haffejee et al., 1990; Jayashree et al.,
1988; Kilgore et al., 1996; Linhares et al., 2002; Madeley et
al., 1978; Murphy et al., 1975; Oelofsen et al., 1985; Perez-
Schael et al., 1984; Spencer et al., 1988; Steele and Alex-
ander 1987; Steele et al., 2002; Sukumaran et al., 1992; Tam
et al., 1990; Tietzova et al., 1995; Totterdell et al., 1976;
Tufvesson et al., 1986). That is because the nature of neo-
natal rotavirus infections is uniquely different in many re-
spects from that in older infants or children. For example,
the majority of rotavirus infections in newborns are charac-
teristically asymptomatic or only minimally symptomatic
and usually occur shortly after birth, and in some cases24
h after birth (Haffejee et al., 1990). Moreover, a majority of
such endemic nursery strains have been shown to carry a
distinct VP4 gene P[6] allele which had not been detected
until recently among circulating community rotavirus
strains that were associated with diarrhea in older children.
It is astonishing to note that rotavirus strains carrying
P1A[8] specificity, which constitutes the majority of field
isolates in diarrheal patients worldwide (Gentsch et al.,
1996; Hoshino and Kapikian, 2000; Kapikian et al., 2001;
Koshimura et al., 2000), have never been documented to
cause endemic and predominantly symptom-free infections
in neonates. It is also noteworthy that another common VP4
serotype P1B[4] has not been observed to cause endemic
and predominantly asymptomatic infections in neonates.
It is still an unsettled issue as to what factors (both host
and viral) are responsible for establishing endemic, predom-
inantly asymptomatic, or mild P[6] rotavirus infections in
neonates. Earlier studies explored possible host factors in-
volved in the unique P[6] rotavirus-neonate ecosystems
such as maternal antibody, soluble and cellular components
in breast milk, intestinal bacterial flora, physiologic imma-
turity of the infant gut, and birth weight of the neonate (for
reviews, see Haffejee, 1991; Hoshino et al., 1985, and
references therein). As for viral factors, we previously re-
ported that no correlation existed between the occurrence of
asymptomatic or mild infections in neonates and a unique
rotavirus VP7 (G) serotype or subgroup (Hoshino et al.,
1985). Previously, the VP4 of two symptomatic P[6] strains
(MW23 and US1205) were reported to be related antigeni-
cally in a one-way fashion to asymptomatic (ST3) VP4. In
the present study, we showed by two-way cross-neutraliza-
tion that both asymptomatic (M37 and ST3) and symptom-
atic (MW23 and US1205) bore similar, if not identical, VP4
neutalization specificities. In addition, the VP4 of two ad-
ditional symptomatic strains (INL1 and R143) was shown to
be related serotypically in a one-way fashion to asymptom-
atic (M37 and ST3) VP4s. Thus, an asymptomatic or symp-
tomatic P[6] rotavirus infection was not associated with
unique VP4(P) serotypes in the limited number of strains
examined in this study. These serological relationships
among P[6] VP4s correlate well with molecular relation-
ships among them: strains M37, 1076, McN, ST3 MW23,
and US1205 share 94% amino acid identity. In addition,
we showed that guinea pig hyperimmune antisera raised
against asymptomatic or symptomatic human P2A[6] or
P?[6] rotavirus VP4 neutralized porcine P2B[6] rotavirus
Gottfried strain efficiently with titers ranging from identical
to eight-fold less than to the homotypic human P2A[6]
strains. Antibodies to Gottfried VP4, however, neutralized
human P2A[6] or P?[6] rotavirus strains recovered from
asymptomatic or symptomatic infections 8- to 16-fold less
efficiently than the homologous Gottfried strain. Thus, be-
cause of the more efficient neutralization, the established
human P2A[6] rotavirus strains could be considered as
prime strains relative to the Gottfried strain. Thus, this is in
accord with a designation of the Gottfried virus as a subtype
(P2B[6]) strain as suggested by Li and Gorziglia (1993).
However, as noted earlier, our neutralization results were
not in agreement with this latter study, which found signif-
icant neutralization of neonatal P2A strains by antiserum to
a Gottfried virus recombinant VP4 but did not find signif-
icant neutralization of Gottfried virus by antiserum to a P2A
neonatal strain recombinant VP4.
Previously, Chen et al. reported that a cross-reactive,
neutralizing VP4-specific epitope was affected by specific
interactions between the VP4 and VP7 of selected reassor-
tants (Chen et al., 1992). More recently, Pesavento et al.
reported that the subtle alterations in VP4 conformation in
certain reassortants were responsible for such altered VP4
phenotype (Pesavento et al., 2003). However, the effect of
such alterations in VP4 conformation in reassortants on the
expression of anti-VP4 neutralizing antibodies as a whole
has never been studied. In this study, we analyzed whether
any qualitative and quantitative differences could be de-
tected in anti-M37 VP4 neutralizing antibodies raised
against reassortants M37  DS-1 (P2A[6],G2) or M37 
UK (P2A[6],G6) and showed that there were no appreciable
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differences in neutralizing capabilities between the two anti-
M37 VP4 antibodies.
As noted earlier, two of the endemic nursery P[6] rota-
virus isolates (Venezuelan M37 strain or Australian RV3
strain) have been developed independently by us and others
as candidate vaccines and undergone phase I to a limited
phase II clinical trials (Barnes et al., 1997, 2002; Flores et
al., 1990; Midthun et al., 1991; Perez-Schael et al., 1994;
Vesikari et al., 1991). Both M37 (P2A[6],G1) and RV3
(P2A[6], G3) vaccines have been shown to be satisfactorily
attenuated and immunogenic in infants. Studies with the
M37 have been discontinued; however, the RV3 candidate
is under study as stated earlier.
Development of a porcine rotavirus strain Gottfried
(P2B[6],G4)-based reassortant vaccine, which incorporates
human rotavirus VP7 (G1, G2, G3 or G9) or VP4 (P1A[8]
or P1B[4]) genes of epidemiologic importance, may repre-
sent an interesting approach because it could provide (i) an
attenuation phenotype of a porcine rotavirus in humans and
(ii) antigenic coverage not only for VP7 and VP4 serotypes
of epidemiologic importance but also for P2A[6] serotype,
which in some parts of the world appears to be of clinical
significance.
Materials and methods
Rotavirus strains, cell cultures, virus titration,
neutralization assay, and hyperimmune antiserum
Table 1 summarizes the rotavirus strains used in this
study. Four P2A[6] rotavirus strains recovered from asymp-
tomatic neonates were M37 from Venezuela, 1076 from
Sweden, McN from Australia, and ST3 from the United
Kingdom. Four P2A[6] or P?[6] rotavirus strains derived
from symptomatic infections were MW23 from Malawi,
US1205 from the United States, INL1 from India, and R143
from Brazil. P and G types and year of collection of each of
the eight P[6] strains are shown in Table 1. Primary cultures
of African green monkey kidney (AGMK) cells (Whittaker
Bioproducts, Walkersville, MD) or an established monkey
kidney MA104 cell line were used for genetic reassortment,
plaque purification, and virus amplification. The MA104
cell line was used for virus titration and plaque reduction
neutralization (PRN) assay. Eagle’s minimum essential me-
dium supplemented with 0.5 g/ml trypsin (Sigma -irra-
diated trypsin, Sigma Chemical, St. Louis, MO) and anti-
biotics were used as maintenance medium. Hyperimmune
antiserum to each of the reassortants was raised in specific
pathogen-free guinea pigs (National Cancer Institute, Fred-
erick, MD), which were free of rotavirus neutralizing anti-
bodies (titer  1:20 versus M37) as determined by PRN
assay. Rotavirus immunogens were prepared as previously
described (Wyatt et al., 1982).
Generation, identification, and characterization of
single gene substitution rotavirus reassortants
Roller tube cultures of primary AGMK or MA104 cells
were coinfected at a multiplicity of infection of approxi-
mately 1 with (i) the M37 virus and the DS-1 virus, (ii) the
M37 virus and the UK virus, (iii) the ST3 virus and the
DS-1 virus, (iv) the MW23 virus and the UK virus, (v) the
US1205 virus and the UK virus, or (vi) the Gottfried virus
and the DS-1 virus. When approximately 75% of the in-
fected cells exhibited cytopathic effects, the cultures were
frozen and thawed once and the lysate was plated onto
primary AGMK or MA104 cells in a six-well plate in the
presence of (i) G1-specific VP7 neutralizing monoclonal
antibody (N-mAb) 2C9 (Shaw et al., 1985) for selection of
the desired M37  DS-1 (P2A[6],G2) or M37  UK
(P2A[6],G6), (ii) G4-specific N-mAb ST-2G7 (Taniguchi et
al., 1987) for selection of the desired ST3  DS-1
(P2A[6],G2) or Gottfried  DS-1 (P2B[6],G2), (iii) guinea
pig hyperimmune antiserum to human rotavirus 69M strain
(P4[10],G8) for selection of the desired MW23  UK
(P2A[6],G6), or (iv) guinea pig hyperimmune antiserum to
human rotavirus WI61 strain (P1A[8],G9) for selection of
the desired US1205 UK (P2A[6],G6). Each of the desired
reassortants was selected and identified and then plaque
purified three times. Each plaque-purified reassortant was
examined for G serotype by enzyme-linked immunosorbent
assay using type-specific VP7 N-mAbs including G6-spe-
cific UK/7 (Snodgrass et al., 1990) as described previously
(Green et al., 1990). The origin of genes of each reassortant
was identified by polyacrylamide gel electrophoresis
(PAGE) of its genomic RNAs. The origin of certain genes
which was not able to be determined with certainty by
PAGE was studied further by constant denaturant gel elec-
trophoresis (CDGE) as previously described (Jones et al.,
2003). Hyperimmune guinea pig antiserum to each reassor-
tant was tested for antibodies to selected human and animal
rotavirus strains by 60% PRN assay (Hoshino et al., 1998).
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